Investor Relations

English Français

Latest News

Feb 11, 2026

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

View Press Release

Feb 3, 2026

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Nov 20, 2025

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

View All News

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Q3 2026

Quarter Ended Dec 31, 2025

Earnings Release

PDF HTML

Audio

Earnings Webcast

Management Discussion & Analysis

PDF

Financial Statements

PDF

Company Overview

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.

GRAFAPEX, an alkylating drug indicated for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation, represents a significant growth opportunity for Medexus. This is driven by its potential to address unmet needs in transplant medicine and expand the company’s presence within hematology-oncology. With increasing adoption across transplant centers, GRAFAPEX could become a key driver of revenue growth and long-term value creation for the company.

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada
T: 877-422-5242